p53 deficiency linked to B cell translocation gene 2 (BTG2) loss enhances metastatic potential by promoting tumor growth in primary and metastatic sites in patient-derived xenograft (PDX) models of triple-negative breast cancer
Emily Powell(The University of Texas MD Anderson Cancer Center), Helen Piwnica‐Worms(Washington University in St. Louis)
Cited by 50
Related Papers
The Chk1 Protein Kinase and the Cdc25C Regulatory Pathways Are Targets of the Anticancer Agent UCN-01
|Journal of Biological Chemistry|2000|541
Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models
|Journal of Clinical Investigation|2012|222
CRL4<sup>CDT2</sup> Targets CHK1 for PCNA-Independent Destruction
|Molecular and Cellular Biology|2012|79
A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies
|Cancer Chemotherapy and Pharmacology|2010|69